Printer Friendly

Isis Pharmaceuticals starts phase 2 study evaluating ISIS-FXIRx.

M2 EQUITYBITES-October 30, 2012-Isis Pharmaceuticals starts phase 2 study evaluating ISIS-FXIRx(C)2012 M2 COMMUNICATIONS

Isis Pharmaceuticals Inc (NASDAQ: ISIS), a company involved in antisense technology to discover and develop novel drugs for its product pipeline and for its partners, has started a phase 2 comparator-controlled study, evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also called total knee arthroplasty, it was reported yesterday.

The medicine inhibits the production of Factor XI, a coagulation factor produced in the liver that is involved in the formation of blood clots.

In this study the company will evaluate the effectiveness of the medicine in decreasing the number of thrombotic events in patients after TKA, without increasing bleeding.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Report
Date:Oct 30, 2012
Previous Article:Outokumpu to get EC nod for Inoxum buy - report.
Next Article:Par Pharmaceutical signs contract with Handa Pharmaceuticals.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters